Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory MyelofibrosisBusiness Wire • Wednesday
Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull CaseSeeking Alpha • Monday
Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDSBusiness Wire • Monday
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of DirectorsBusiness Wire • 11/28/23
Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDSBusiness Wire • 11/02/23
Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial ResultsBusiness Wire • 11/02/23
Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDSBusiness Wire • 09/29/23
Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial OfficerBusiness Wire • 09/11/23
Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual MeetingBusiness Wire • 09/07/23
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDSBusiness Wire • 08/21/23
Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial ResultsBusiness Wire • 08/03/23